Planning of Parkinson's disease treatment considering the motor cortical plasticity
Project/Area Number |
25461322
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Neurology
|
Research Institution | Fukushima Medical University |
Principal Investigator |
|
Co-Investigator(Renkei-kenkyūsha) |
UGAWA Yoshikazu 福島県立医科大学, 医学部, 教授 (50168671)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
|
Keywords | 神経可塑性 / パーキンソン病 / ドーパミン / プラミペキソール |
Outline of Final Research Achievements |
We applied quadripulse stimulation (QPS) over the primary motor cortex (M1) in 10 normal subjects to induce bidirectional long-term motor cortical plasticity. A long-term potentiation (LTP)-like effect was induced by high frequency QPS5 over M1, whereas a long-term depression (LTD)-like effect was induced by low frequency QPS50. In a double blind randomized placebo-controlled crossover design, either L-Dopa carbidopa 100mg, pramipexole 1.5mg, or placebo was administered to the subjects 30 minutes before applying QPS. L-Dopa enhanced both LTP- and LTD-like plasticity as compared to placebo. In contrast, neither an LTP-like effect nor an LTD-like effect was modulated by pramipexole. The lack of LTP enhancement by pramipexole is compatible with the finding that D1 activation strengthens LTP because pramipexole is almost purely a D2 agonist. The lack of LTD enhancement by pramipexole is also consistent with the finding that both D1 and D2 coactivation is required for LTD.
|
Report
(4 results)
Research Products
(5 results)